EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Pleural Space Diseases and Their Management: What is the Role of Intrapleural Fibrinolytic Therapy?

Halima A Siddiqui iD, Elizabeth R Maginot iD, Trace B Moody, Reynold Henry, Christopher D Barrett

The American Surgeon™ · 2025

DOI: 10.1177/00031348251331281 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The American Surgeon™, 2025. Verfasst von Halima A Siddiqui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Acute Care Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA. Hauptthemen laut MEDLINE: Thrombolytic Therapy, Fibrinolytic Agents, Pleural Diseases, Tissue Plasminogen Activator. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pleural space diseases are a significant cause of morbidity in the United States with a reported 25% mortality rate within a year of diagnosis. Pleural space diseases, including intrapleural infections, retained hemothorax (RH), and malignant pleural effusions (MPE), often indicate advanced disease. Despite options like video-assisted thoracoscopy (VATS), tube thoracostomy, and intrapleural fibrinolytic therapy (IPFT), treatment remains a significant clinical challenge. IPFT, which describes a combination of administrating tissue plasminogen activator (tPA) and DNase through a chest tube, has shown effectiveness in improving fluid drainage and reducing surgery frequency in a large, randomized control trial and is widely used. However, the success of IPFT varies based on infection severity, patient health, and treatment timing, with a failure rate around 20-25%. This highlights the need for further research to enhance the therapy’s efficacy, investigating both disease mechanisms and optimizing treatment protocols. This review seeks to provide a comprehensive overview of IPFT, highlighting recent advancements, current trends, and existing research gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombolytic TherapyFibrinolytic AgentsPleural DiseasesTissue Plasminogen ActivatorHumansHemothoraxChest TubesDeoxyribonucleasesThoracic Surgery, Video-Assisted

Stichwörter der Autor:innen

Intrapleural Fibrinolytic Therapyintrapleural infectionspleural space diseasesretained hemothorax (RH)tPA and DNase

Substanzen

Fibrinolytic AgentsTissue Plasminogen ActivatorDeoxyribonucleases

Autor:innen und Institutionen

  • Division of Acute Care Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
  • Division of Trauma, Critical Care and Acute Care Surgery, Oregon Health and Science University, Portland, OR, USA.
  • Department of Cellular and Integrative Physiology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

ORCID-Profile: Halima A Siddiqui, Elizabeth R Maginot

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Siddiqui, H. A., Maginot, E. R., Moody, T. B., Henry, R., & Barrett, C. D. (2025). Pleural Space Diseases and Their Management: What is the Role of Intrapleural Fibrinolytic Therapy?. The American Surgeon™. https://doi.org/10.1177/00031348251331281

Vancouver

Siddiqui HA, Maginot ER, Moody TB, Henry R, Barrett CD. Pleural Space Diseases and Their Management: What is the Role of Intrapleural Fibrinolytic Therapy?. The American Surgeon™. 2025. doi:10.1177/00031348251331281

BibTeX
@article{Siddiqui2025,
  author = {Siddiqui, Halima A and Maginot, Elizabeth R and Moody, Trace B and Henry, Reynold and Barrett, Christopher D},
  title = {Pleural Space Diseases and Their Management: What is the Role of Intrapleural Fibrinolytic Therapy?},
  journal = {The American Surgeon™},
  year = {2025},
  doi = {10.1177/00031348251331281}
}
Kostenlos starten →